XML 45 R34.htm IDEA: XBRL DOCUMENT v3.25.3
REVENUES - Summary of Total Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Disaggregation of Revenue [Line Items]        
Total revenues $ 7,769 $ 7,545 $ 21,518 $ 21,185
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,281 5,450 15,000 15,024
Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,555 1,167 3,828 3,459
Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 933 929 2,690 2,703
Total product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 7,345 7,515 21,013 21,074
Total product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,274 5,433 14,943 14,958
Total product sales | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,144 1,154 3,395 3,416
Total product sales | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 928 928 2,674 2,700
Total HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 5,277 5,073 14,952 14,160
Total HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,299 4,161 12,059 11,386
Total HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 592 570 1,769 1,737
Total HIV | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 386 342 1,124 1,038
Biktarvy        
Disaggregation of Revenue [Line Items]        
Total revenues 3,686 3,472 10,366 9,649
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2,940 2,826 8,212 7,726
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 427 375 1,231 1,110
Biktarvy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 320 272 922 814
Descovy        
Disaggregation of Revenue [Line Items]        
Total revenues 701 586 1,939 1,496
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 652 534 1,791 1,339
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 23 24 67 75
Descovy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 25 28 81 82
Genvoya        
Disaggregation of Revenue [Line Items]        
Total revenues 377 449 1,118 1,292
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 323 384 950 1,088
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 34 44 114 138
Genvoya | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 19 21 54 66
Odefsey        
Disaggregation of Revenue [Line Items]        
Total revenues 277 326 857 952
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 206 248 642 705
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 61 69 184 217
Odefsey | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 10 9 30 30
Symtuza - Revenue share        
Disaggregation of Revenue [Line Items]        
Total revenues 124 139 362 448
Symtuza - Revenue share | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 95 103 265 338
Symtuza - Revenue share | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 26 33 88 101
Symtuza - Revenue share | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 9 9
Other HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 112 100 310 322
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 82 65 198 190
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 22 26 85 96
Other HIV | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 9 9 28 36
Total Liver Disease        
Disaggregation of Revenue [Line Items]        
Total revenues 819 733 2,372 2,302
Total Liver Disease | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 414 393 1,162 1,210
Total Liver Disease | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 158 132 496 411
Total Liver Disease | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 247 207 714 682
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Total revenues 309 385 996 1,266
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 146 222 497 737
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 65 67 227 230
Sofosbuvir/Velpatasvir | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 97 96 273 299
Vemlidy        
Disaggregation of Revenue [Line Items]        
Total revenues 280 232 783 699
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 136 126 358 338
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 12 11 36 33
Vemlidy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 132 95 389 328
Other Liver Disease        
Disaggregation of Revenue [Line Items]        
Total revenues 231 116 593 337
Other Liver Disease | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 132 45 307 134
Other Liver Disease | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 81 54 233 148
Other Liver Disease | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 17 17 53 55
Veklury        
Disaggregation of Revenue [Line Items]        
Total revenues 277 692 700 1,461
Veklury | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 140 393 390 784
Veklury | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 43 81 84 204
Veklury | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 93 219 225 473
Total Oncology        
Disaggregation of Revenue [Line Items]        
Total revenues 788 816 2,395 2,446
Total Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 384 433 1,192 1,338
Total Oncology | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 275 291 821 828
Total Oncology | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 129 92 381 280
Total Cell Therapy        
Disaggregation of Revenue [Line Items]        
Total revenues 432 485 1,381 1,485
Total Cell Therapy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 163 208 566 683
Total Cell Therapy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 186 211 562 611
Total Cell Therapy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 83 66 253 192
Tecartus        
Disaggregation of Revenue [Line Items]        
Total revenues 83 98 254 305
Tecartus | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 40 63 122 181
Tecartus | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 35 29 107 102
Tecartus | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 8 6 25 22
Yescarta        
Disaggregation of Revenue [Line Items]        
Total revenues 349 387 1,127 1,181
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 123 145 444 502
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 151 182 455 509
Yescarta | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 75 60 228 170
Trodelvy        
Disaggregation of Revenue [Line Items]        
Total revenues 357 332 1,013 960
Trodelvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 221 226 626 655
Trodelvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 89 80 259 217
Trodelvy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 47 26 128 88
Total Other        
Disaggregation of Revenue [Line Items]        
Total revenues 184 201 594 705
Total Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 36 53 140 241
Total Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 76 80 225 236
Total Other | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 72 68 230 228
AmBisome        
Disaggregation of Revenue [Line Items]        
Total revenues 123 130 391 424
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2 6 15 37
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 69 71 201 210
AmBisome | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 52 52 175 176
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 61 71 204 281
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 34 47 125 203
Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 7 8 23 26
Other | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 20 16 55 52
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Total revenues 424 30 505 111
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 7 17 57 66
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 411 13 433 43
Royalty, contract and other revenues | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues $ 5 $ 1 $ 16 $ 2